China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $821M is the value of all shares combined. Beta 0.74: the stock has moved about 26% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerChina Traditional Chinese Medicine Holdings Co. Limited (CHIZF) trades at $0.1631. China Traditional Chinese Medicine Holdings Co. Limited researches, develops, produces, and sells Chinese medicine and pharmaceutical products. Market cap: $821M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for CHIZF: CHIZF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CHIZF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
CHIZF: 1/2 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) Healthcare & Pipeline Overview
China Traditional Chinese Medicine Holdings Co. Limited, established in 1573, focuses on researching, developing, producing, and selling traditional Chinese medicine and pharmaceutical products. Operating primarily in the People's Republic of China, the company offers a diverse portfolio of TCM products, including granules, finished drugs, and decoction pieces, catering to hospitals and retail pharmacies.
What Is the Investment Thesis for CHIZF?
China Traditional Chinese Medicine Holdings Co. Limited presents a mixed investment profile. The company's long history and established presence in the Chinese TCM market provide a solid foundation. However, the company's negative profit margin of -1.7% and negative ROE of -1.4% raise concerns about profitability and efficiency. With a market capitalization of $821M and a debt-to-equity ratio of 15.38, the company appears financially stable, but the lack of free cash flow ($0.00B) is a concern. Growth catalysts include expanding its product line and increasing its market share within China. The beta of 0.74 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
CHIZF Key Highlights
Market capitalization of $821M, indicating a significant presence in the TCM market.
- Gross margin of 47.7%, reflecting a strong ability to manage production costs.
- Debt-to-equity ratio of 15.38, suggesting a conservative approach to financial leverage.
- Beta of 0.74, indicating lower volatility compared to the overall market.
- Founded in 1573, demonstrating a long-standing history and established brand in the TCM industry.
Who Are CHIZF's Competitors?
CHIZF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| GNMLF Genomma Lab Internacional, S.A.B. de C.V. | $0.78 | 0.00% | $761M | 529-signal |
| COLL Collegium Pharmaceutical, Inc. | $22.92 | -1.88% | $743M | 745-pillar |
| PCRX Pacira BioSciences, Inc. | $25.16 | -2.78% | $990M | 875-pillar |
| IRWD Ironwood Pharmaceuticals, Inc. | $4.07 | +2.39% | $669M | 385-pillar |
| AMPH Amphastar Pharmaceuticals, Inc. | $23.54 | +2.17% | $1.04B | 765-pillar |
| CRON Cronos Group Inc. | $3.16 | +0.16% | $1.18B | 905-pillar |
| HROW Harrow Health, Inc. | $36.58 | -2.58% | $1.36B | 529-signal |
| KMDA Kamada Ltd. | $7.99 | -2.68% | $461M | 815-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are CHIZF's Key Strengths?
Long-standing history and established brand in the TCM market.
- Integrated operations, from herb cultivation to product distribution.
- Diverse product portfolio catering to various healthcare needs.
- Established distribution network across China.
What Are CHIZF's Weaknesses?
Negative profit margin and return on equity.
- Lack of free cash flow.
- Reliance on the Chinese market.
- Potential quality control issues in TCM production.
What Could Drive CHIZF Stock Higher?
Expansion of product lines to include innovative TCM formulations.
- Geographic expansion within China to underserved regions.
- Increased investment in R&D to develop evidence-based TCM products.
- Strategic partnerships and acquisitions to expand capabilities.
- Leveraging e-commerce platforms to reach a wider customer base.
What Are the Key Risks for CHIZF?
Financial-distress signal — its Altman Z-Score of 1.70 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-1.7%) — the business is not currently generating profit on shareholder capital.
- Stringent regulations and quality control requirements in the pharmaceutical industry.
- Competition from both domestic and international pharmaceutical companies.
- Fluctuations in the prices of raw materials.
- Adverse events related to TCM products.
- Negative profit margin and return on equity.
What Are the Growth Opportunities for CHIZF?
- Expansion of TCM Product Lines: China Traditional Chinese Medicine Holdings Co. Limited can capitalize on the growing demand for TCM by expanding its product lines to include innovative formulations and specialized treatments. The global herbal medicine market is projected to reach $129.3 billion by 2028, presenting a significant opportunity for growth. This expansion can be achieved through internal research and development or strategic acquisitions of smaller TCM companies.
- Geographic Expansion within China: The company can further penetrate the Chinese market by expanding its distribution network to reach underserved regions and populations. The Chinese pharmaceutical market is the second-largest in the world, with significant growth potential in rural areas. This expansion can be facilitated through partnerships with local distributors and the establishment of new retail outlets.
- Increased Investment in R&D: Investing in research and development to create new TCM products and improve existing formulations can drive future growth. The company can focus on developing evidence-based TCM products that meet international quality standards. This will not only enhance the company's competitiveness but also open up opportunities for export to international markets.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with other pharmaceutical companies, research institutions, and healthcare providers can accelerate growth and expand the company's capabilities. Acquisitions of complementary businesses can provide access to new technologies, markets, and product lines. These partnerships can also facilitate the development of new TCM products and the improvement of existing formulations.
- Leveraging E-commerce Platforms: The company can leverage e-commerce platforms to reach a wider customer base and increase sales. Online sales of TCM products are growing rapidly in China, driven by the increasing popularity of online shopping. By establishing a strong online presence, the company can tap into this growing market and increase its revenue.
What Are CHIZF's Competitive Advantages?
- Established Brand: The company has a long-standing history and a well-recognized brand in the Chinese TCM market, dating back to 1573.
- Integrated Operations: The company's integrated operations, including cultivation of medicinal herbs, manufacturing, and distribution, provide a competitive advantage.
- Extensive Product Portfolio: The company offers a diverse portfolio of TCM products, catering to a wide range of healthcare needs.
- Distribution Network: The company has an established distribution network, reaching hospitals and retail pharmacies across China.
What Does CHIZF Do?
China Traditional Chinese Medicine Holdings Co. Limited, tracing its origins back to 1573, is an investment holding company deeply rooted in the research, development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products. Headquartered in Wan Chai, Hong Kong, the company operates primarily within the People's Republic of China. Its comprehensive product portfolio includes granules, finished drugs, decoction pieces, and healthcare products, catering to a broad spectrum of healthcare needs. Beyond its core manufacturing activities, China Traditional Chinese Medicine Holdings Co. Limited is involved in the cultivation and management of Chinese medicinal herbs, ensuring a consistent supply of high-quality raw materials. The company also engages in the trading of pharmaceutical products, provision of TCM marketing, advertising, and consulting services, and retail of pharmaceuticals and decoction products. These diverse activities enable the company to serve hospitals and retail pharmacies effectively. Formerly known as China Traditional Chinese Medicine Co. Limited, the company adopted its current name in July 2016, reflecting its evolution and expanded scope of operations. The company also provides property leasing services.
What Products and Services Does CHIZF Offer?
- Researches and develops traditional Chinese medicine (TCM) products.
- Produces a range of TCM products, including granules, finished drugs, and decoction pieces.
- Sells its TCM products to hospitals and retail pharmacies.
- Cultivates and manages Chinese medicinal herbs.
- Trades pharmaceutical products.
- Provides TCM marketing, advertising, and consulting services.
- Engages in the retail of pharmaceuticals and decoction products.
- Provides property leasing services.
How Does CHIZF Make Money?
- Develops and manufactures TCM products.
- Generates revenue through the sale of TCM products to hospitals and retail pharmacies.
- Supplements revenue through trading of pharmaceutical products and provision of TCM-related services.
- Derives income from property leasing activities.
What Industry Does CHIZF Operate In?
China Traditional Chinese Medicine Holdings Co. Limited operates within the growing Chinese pharmaceutical market, specifically focusing on traditional Chinese medicine. The TCM market is driven by increasing consumer awareness of natural remedies and government support for the industry. However, the industry faces challenges such as stringent regulations, quality control issues, and competition from both domestic and international players. The company's established presence and integrated operations provide a competitive advantage, but it must navigate these challenges to maintain its market position.
Who Are CHIZF's Key Customers?
- Hospitals throughout China.
- Retail pharmacies across China.
- Patients seeking TCM treatments.
- Other pharmaceutical companies (through trading activities).
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
- ● Reported in CNY, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 44 |
| 2026-08-26 | 44 |
| 2026-08-29 | 44 |
| 2026-09-01 | 44 |
| 2026-09-04 | 44 |
| 2026-09-07 | 44 |
| 2026-09-10 | 44 |
What changed?
The score has stayed at 44.
Over the same 18 days the stock moved +0.0%.
Company Profile
China Traditional Chinese Medicine Holdings Co. Limited operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Hong Kong, HK. The company is led by CEO Jun Yang. CHIZF has traded publicly since 2021.
China Traditional Chinese Medicine Holdings Co. Limited Financial Trajectory
China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) reported $801.1M in revenue for Q2 FY2026, a decline of 25.1% compared to the prior quarter. The company recorded a net loss of $114.3M, with diluted EPS of $-0.02. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, CHIZF averaged $-0.01 in diluted EPS.
How China Traditional Chinese Medicine Holdings Co. Limited Is Valued
China Traditional Chinese Medicine Holdings Co. Limited carries a market capitalization of $821M, placing it in the small-cap category.
Key Financial Metrics
Return on equity for China Traditional Chinese Medicine Holdings Co. Limited stands at -1.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.1%, showing how much profit it generates from its asset base. Its free cash flow yield is 27.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.29 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -5.8%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
China Traditional Chinese Medicine Holdings Co. Limited's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.70 places it in the distress zone, a signal of elevated financial risk.
CHIZF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Long-standing history and established brand in the TCM market.
- Integrated operations, from herb cultivation to product distribution.
- Diverse product portfolio catering to various healthcare needs.
- Established distribution network across China.
Bear Case
- Negative profit margin and return on equity.
- Lack of free cash flow.
- Reliance on the Chinese market.
- Potential quality control issues in TCM production.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $801M | -$114M | -$0.02 |
| Q4 FY2025 | $1.07B | -$34M | -$0.01 |
| Q2 FY2025 | $557M | -$8M | -$0.0016 |
| Q4 FY2024 | $1.21B | -$23M | -$0.0047 |
Q2 FY2026 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from CNY at today's rate
CHIZF Latest News
No recent news available for CHIZF.
CHIZF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CHIZF.
Price Targets
Wall Street price target analysis for CHIZF.
CHIZF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CHIZF; grades run from A+ (80-100) to F (below 30).
Leadership: Jun Yang
Unknown
Further research would be needed to provide a comprehensive profile.
Track Record: Information on Jun Yang's track record is not available in the provided data. Further research would be needed to provide a detailed assessment.
CHIZF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that China Traditional Chinese Medicine Holdings Co. Limited may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB, or major exchanges like NYSE or NASDAQ. Companies in this tier often have limited operating history, are thinly traded, and may not be subject to stringent regulatory oversight. This contrasts with listed exchanges, which have specific listing standards and reporting requirements designed to protect investors.
- OTC Tier: OTC Other
- Limited Disclosure: OTC companies often have less stringent disclosure requirements, making it difficult to assess their financial health and operational performance.
- Low Liquidity: OTC stocks can be thinly traded, leading to wide bid-ask spreads and difficulty in buying or selling shares.
- Regulatory Oversight: OTC markets are subject to less regulatory oversight than major exchanges, increasing the risk of fraud and manipulation.
- Price Volatility: OTC stocks can be more volatile than those listed on major exchanges due to lower trading volumes and less institutional interest.
- Information Asymmetry: Limited access to information can create an uneven playing field for investors.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the company's management team and corporate governance.
- Check for any legal or regulatory issues.
- Monitor trading activity and liquidity.
- Consult with a financial advisor.
- Long operating history (founded in 1573).
- Presence in the Chinese market.
- Number of employees (16753).
- Tangible business operations (research, development, production, and sale of TCM products).
- Involvement in the cultivation of Chinese medicinal herbs.
Common Questions About CHIZF (Healthcare)
Is CHIZF a good stock?
Stock Expert AI does not rate CHIZF buy, sell or hold. China Traditional Chinese Medicine Holdings Co. Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What does China Traditional Chinese Medicine Holdings Co. Limited do?
China Traditional Chinese Medicine Holdings Co. Limited is involved in the research, development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products. The company offers a range of products, including granules, finished drugs, decoction pieces, and healthcare products.
What are the key factors to evaluate for CHIZF?
Evaluate CHIZF on fundamentals, analyst consensus, and risk factors. China Traditional Chinese Medicine Holdings Co. Limited presents a mixed investment profile. Not financial advice.
How frequently does CHIZF data refresh on this page?
CHIZF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CHIZF's recent stock price performance?
China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Long-standing history and established brand in the TCM market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CHIZF overvalued or undervalued right now?
China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of CHIZF?
Yes, most major brokerages offer fractional shares of China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CHIZF's earnings and financial reports?
China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for CHIZF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than data for listed exchanges.